nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

01.09.2007 | Original Paper

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

verfasst von: Muammer Karadeniz, Mehmet Erdogan, Afig Berdeli, Fusun Saygili, Candeger Yilmaz

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system.

Methods

Eighty-six young women with PCOS and 70 healthy control women were included in our study. PCOS patients and controls were matched for age, body mass index, and allele frequency. Genetic analysis of TPAI and PAI-1 were performed in all subjects.

Results and conclusions

No statistically significant differences have been detected about the ratios of genotypes resulting from PAI-1 promotor 4G/5G gene polymorphism. PAI-1 765 4G/5G gene polymorphism and TPA gene’s Alu-repeat insertion/deletion (I/D) polymorphism ratios were not different from the controls. In this study it is shown by the analysis of TPA gene’s Alu-repeat insertion/deletion (I/D) polymorphism the PCOS patients with genotype II had lowers total cholesterol and LDL-cholesterol levels.

Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191(3):713–7.PubMedCrossRef

Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302–12.PubMedCrossRef

Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143–50.PubMedCrossRef

Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98:27S–32S.PubMedCrossRef

Chambers JC, Kooner JS. Homocysteine: a novel risk factor for coronary heart disease in UK Indian Asians. Heart 2001;86 2:121–2.PubMedCrossRef

Kannel WB, D’Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672–6.PubMedCrossRef

Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666–73.PubMedCrossRef

Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851–5.PubMedCrossRef

Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996;45:623–9.CrossRef

10.

Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121–6.PubMed

11.

Grancha S, Estelles A, Torno G, Falco C, Gilabert J, Espana F, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999;81:516–21.PubMed

12.

Degen SJ, Rajput B, Reich E. The human tissue plasminogen activator gene. J Biol Chem 1986;25;261(15):6972–85.

13.

van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial TPA synthesis. Thromb Haemost 1995;74:1202.PubMed

14.

The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19 1:41–7.CrossRef

15.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.PubMedCrossRef

16.

Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 2002;74:1147–52.PubMedCrossRef

17.

Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067–72.PubMedCrossRef

18.

Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004;150:793–8.PubMedCrossRef

19.

Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000;49:845–52.PubMedCrossRef

20.

Glueck CJ, Awadalla SG, Phillips H, Cameron D, Wang P, Fontaine RN. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil Steril 2000;74:394–7.PubMedCrossRef

21.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589–95.PubMedCrossRef

22.

Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:46–52.PubMedCrossRef

23.

Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:323–34.PubMedCrossRef

24.

Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003;52:1627–32.PubMedCrossRef

25.

Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994;61:455–60.PubMed

26.

Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975–9.PubMed

27.

Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G, et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Resolution 1994;25:85–92.

28.

Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37–42.PubMedCrossRef

29.

Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin levels and relative body weight in normal and obese subjects. Metabolism 1986;35:250–3.PubMedCrossRef

30.

Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C. Genetic variation at the human tissue-type plasminogen activator (TPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003;11:603–10.PubMedCrossRef

31.

Sartori MT, Saggiorato G, Spiezia L, Varvarikis C, Carraro G, Patrassi GM, et al. Influence of the Alu-repeat I/D polymorphism in TPA gene intron 8 on the stimulated TPA release after venous occlusion. Clin Appl Thromb Hemost 2003;9:63–9.PubMedCrossRef

32.

McCormack LJ, Nagi DK, Stickland MH, Mansfield MW, Mohamed-Ali V, Yudkin JS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia 1996;39:1512–18.PubMedCrossRef

33.

Matsubara Y, Murata M, Isshiki I, Watanabe R, Zama T, Watanabe G, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999;69:43–7.PubMed

34.

Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, et al. The role of the TPA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000;99:223–30.PubMedCrossRef

35.

Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165–8.PubMedCrossRef

36.

Carter AM, Catto AJ, Grant PJ. Determinants of TPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 1998;80:632–6.PubMed

37.

van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, deJong PTVM, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study. Circulation 1997;95:2623–7.PubMed

38.

Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality on long term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993;88:2030–4.PubMed

39.

Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006;152 6:1109–15.PubMedCrossRef

40.

Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughn DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (TPA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 1997;17:1687–90.PubMed

41.

Steeds R, Adams M, Smith P, Channer K, Samani NJ. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 1998;79:980–4.PubMed

42.

Ernst E, Resch L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956–63.PubMed

43.

Stone MC, Thorp JM. Plasma fibrinogen—a major coronary risk factor. J R Coll Gen Pract 1985;35:565–9.PubMed

44.

Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997;54(Suppl 3):32–40.PubMedCrossRef

Titel: 4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome
verfasst von: Muammer Karadeniz
Mehmet Erdogan
Afig Berdeli
Fusun Saygili
Candeger Yilmaz
Publikationsdatum: 01.09.2007
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 9/2007
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-007-9160-7

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome

Abstract

Purpose

Methods

Results and conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Update Gynäkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

Prediction of pregnancy in IVF cycles on the fourth day of ovarian stimulation

Analysis of meiotic segregation patterns and interchromosomal effects in sperm from six males with Robertsonian translocations

What is the role of regulatory T cells in the success of implantation and early pregnancy?

Examination of bacterial contamination at the time of embryo transfer, and its impact on the IVF/pregnancy outcome

Sperm motility stimulation and preservation with various concentrations of follicular fluid

Retention of membrane charge attributes by cryopreserved-thawed sperm and zeta selection

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Update Gynäkologie